Boehringer Ingelheim Deal History & Licensing Activity
Boehringer Ingelheim is a large pharma headquartered in Germany. Over the past three years, Boehringer Ingelheim has been involved in 21 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
8
Active Trials
50
Top Modality
Other
Focus Area
Oncology
Boehringer Ingelheim Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Boehringer Ingelheim in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CT-155 | Click Therapeutics | Other | Phase 3 | other | Apr 2026 |
| BI 655066 | AbbVie | Other | Phase 3 | license | Mar 2026 |
| SIRPα-mab | Junshi Biosciences | Bispecific Antibodies | Approved | acquisition | Jan 2026 |
Boehringer Ingelheim Pipeline Focus
Therapeutic areas and modalities where Boehringer Ingelheim is most active based on deal history and clinical trial data.
Therapeutic Areas
Boehringer Ingelheim Strategic Signals
Key indicators of Boehringer Ingelheim's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Boehringer Ingelheim Clinical Pipeline
Boehringer Ingelheim has 50 active clinical trials across 5 development phases.
9
Unknown
3
Not Applicable
19
Phase 1
8
Phase 2
11
Phase 3
See How Your Asset Matches Boehringer Ingelheim's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Boehringer Ingelheim Licensing & Deal Activity
Boehringer Ingelheim is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 21 deals over the past three years, Boehringer Ingelheim ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Boehringer Ingelheim include Oncology (18 deals and trials), Metabolic (5 deals and trials), Solid Tumors (5 deals and trials), and Cardiovascular (3 deals and trials). In terms of modality, Boehringer Ingelheim has shown particular interest in other, bispecific antibodies, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Boehringer Ingelheim and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Boehringer Ingelheim's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.